Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has signed an agreement with Emergent BioSolutions for manufacturing services for its lead investigational Covid-19 vaccine candidate.

The vaccine programme builds on Janssen’s AdVac and PER.C6 technologies.

Under the agreement, worth around $135m, Emergent will offer drug substance manufacturing services using its molecule-to-market CDMO offering.

The services will support investments from J&J starting this year.

Emergent will reserve some large-scale manufacturing capacity to prepare for commercial manufacturing of the adenovirus-based Covid-19 vaccine beginning next year.

The companies are also considering a long-term commercial manufacturing agreement to help reach J&J’s goal of supplying one billion doses of a vaccine against Covid-19.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Emergent will carry out large-scale manufacturing of drug substance for the vaccine candidate at its Baltimore Bayview facility.

Emergent BioSolutions senior vice-president and CDMO business unit head Syed Husain said: “We share with our partners the same urgency to combat Covid-19 and will leverage our talents, capabilities, and capacities up to 300 million doses to advance this much-needed vaccine candidate and ensure ongoing commercial supply through our CDMO services.”

J&J said that preparations for clinical vaccine production are already underway at its facility in Leiden, the Netherlands. The company intends to begin Phase I clinical trials of the vaccine in September this year.

Furthermore, the company plans to rapidly scale-up worldwide vaccine manufacturing capabilities, including boosting of capacity in ex-US countries.

Additional global capacity should enable rapid production of a vaccine and the supply of more than one billion doses globally.

Johnson & Johnson chief scientific officer Paul Stoffels said: “We have set a high bar. Johnson & Johnson has committed to rapidly produce and supply more than one billion doses of a safe and effective vaccine globally. Our collaboration with Emergent is proof that we are moving quickly to deliver on that promise.”

According to J&J, this agreement marks the first of potential global deals to expedite manufacture of its Covid-19 vaccine candidate.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now